QQQ   355.21 (+0.58%)
AAPL   182.14 (+0.87%)
MSFT   328.15 (+0.89%)
META   265.08 (+0.19%)
GOOGL   123.01 (+0.71%)
AMZN   124.24 (+-0.01%)
TSLA   246.82 (+5.09%)
NVDA   390.97 (+1.52%)
NIO   7.83 (+0.51%)
BABA   85.78 (-0.42%)
AMD   125.43 (+3.62%)
T   16.01 (-0.37%)
F   13.78 (+1.47%)
MU   65.55 (+0.35%)
CGC   0.67 (-4.16%)
GE   105.98 (-0.08%)
DIS   91.87 (-0.71%)
AMC   4.74 (+1.28%)
PFE   38.94 (-0.38%)
PYPL   63.59 (-1.01%)
NFLX   421.86 (+3.05%)
QQQ   355.21 (+0.58%)
AAPL   182.14 (+0.87%)
MSFT   328.15 (+0.89%)
META   265.08 (+0.19%)
GOOGL   123.01 (+0.71%)
AMZN   124.24 (+-0.01%)
TSLA   246.82 (+5.09%)
NVDA   390.97 (+1.52%)
NIO   7.83 (+0.51%)
BABA   85.78 (-0.42%)
AMD   125.43 (+3.62%)
T   16.01 (-0.37%)
F   13.78 (+1.47%)
MU   65.55 (+0.35%)
CGC   0.67 (-4.16%)
GE   105.98 (-0.08%)
DIS   91.87 (-0.71%)
AMC   4.74 (+1.28%)
PFE   38.94 (-0.38%)
PYPL   63.59 (-1.01%)
NFLX   421.86 (+3.05%)
QQQ   355.21 (+0.58%)
AAPL   182.14 (+0.87%)
MSFT   328.15 (+0.89%)
META   265.08 (+0.19%)
GOOGL   123.01 (+0.71%)
AMZN   124.24 (+-0.01%)
TSLA   246.82 (+5.09%)
NVDA   390.97 (+1.52%)
NIO   7.83 (+0.51%)
BABA   85.78 (-0.42%)
AMD   125.43 (+3.62%)
T   16.01 (-0.37%)
F   13.78 (+1.47%)
MU   65.55 (+0.35%)
CGC   0.67 (-4.16%)
GE   105.98 (-0.08%)
DIS   91.87 (-0.71%)
AMC   4.74 (+1.28%)
PFE   38.94 (-0.38%)
PYPL   63.59 (-1.01%)
NFLX   421.86 (+3.05%)
QQQ   355.21 (+0.58%)
AAPL   182.14 (+0.87%)
MSFT   328.15 (+0.89%)
META   265.08 (+0.19%)
GOOGL   123.01 (+0.71%)
AMZN   124.24 (+-0.01%)
TSLA   246.82 (+5.09%)
NVDA   390.97 (+1.52%)
NIO   7.83 (+0.51%)
BABA   85.78 (-0.42%)
AMD   125.43 (+3.62%)
T   16.01 (-0.37%)
F   13.78 (+1.47%)
MU   65.55 (+0.35%)
CGC   0.67 (-4.16%)
GE   105.98 (-0.08%)
DIS   91.87 (-0.71%)
AMC   4.74 (+1.28%)
PFE   38.94 (-0.38%)
PYPL   63.59 (-1.01%)
NFLX   421.86 (+3.05%)

Century Therapeutics (IPSC) Competitors

$3.34
-0.07 (-2.05%)
(As of 02:29 PM ET)
Compare
Today's Range
$3.30
$3.53
50-Day Range
$2.91
$3.47
52-Week Range
$2.81
$14.00
Volume
31,719 shs
Average Volume
158,011 shs
Market Capitalization
$199.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

IPSC vs. OPT, BCAB, JSPR, PSTX, GRPH, CCCC, GMDA, GRTS, VXRT, and ABOS

Should you be buying Century Therapeutics stock or one of its competitors? The main competitors of Century Therapeutics include Opthea (OPT), BioAtla (BCAB), Jasper Therapeutics (JSPR), Poseida Therapeutics (PSTX), Graphite Bio (GRPH), C4 Therapeutics (CCCC), Gamida Cell (GMDA), Gritstone bio (GRTS), Vaxart (VXRT), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "biological products, except diagnostic" industry.

Century Therapeutics vs.

Opthea (NASDAQ:OPT) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Opthea has a net margin of 0.00% compared to Century Therapeutics' net margin of -2,127.33%. Opthea's return on equity of 0.00% beat Century Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Opthea N/A N/A N/A
Century Therapeutics -2,127.33% -39.33% -25.10%

Opthea currently has a consensus target price of $22.50, suggesting a potential upside of 614.29%. Century Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 468.86%. Given Opthea's higher possible upside, equities analysts plainly believe Opthea is more favorable than Century Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opthea
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Century Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00

13.9% of Opthea shares are held by institutional investors. Comparatively, 35.8% of Century Therapeutics shares are held by institutional investors. 3.2% of Opthea shares are held by insiders. Comparatively, 7.6% of Century Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Opthea's average media sentiment score of 0.00 equaled Century Therapeutics' average media sentiment score.

Company Overall Sentiment
Opthea Neutral
Century Therapeutics Neutral

Opthea has higher earnings, but lower revenue than Century Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Opthea$90 thousand2,044.00-$92.82 millionN/AN/A
Century Therapeutics$5.20 million38.27-$130.93 million-$2.15-1.55

Opthea has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Century Therapeutics received 8 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 59.46% of users gave Century Therapeutics an outperform vote while only 51.85% of users gave Opthea an outperform vote.

CompanyUnderperformOutperform
OptheaOutperform Votes
14
51.85%
Underperform Votes
13
48.15%
Century TherapeuticsOutperform Votes
22
59.46%
Underperform Votes
15
40.54%

Summary

Century Therapeutics beats Opthea on 7 of the 13 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IPSC vs. The Competition

MetricCentury TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$199.00M$2.60B$4.58B$6.30B
Dividend YieldN/A2.34%2.37%6.18%
P/E Ratio-1.553.32100.3212.49
Price / Sales38.27182.163,300.0488.74
Price / CashN/A16.3291.68113.53
Price / Book0.653.504.705.31
Net Income-$130.93M$53.42M$118.02M$193.02M
7 Day Performance1.21%1.75%1.18%1.68%
1 Month Performance1.21%6.14%1.80%5.33%
1 Year Performance-60.98%10.90%8.62%3.27%

Century Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPT
Opthea
1.5278 of 5 stars
$3.20
+2.2%
$22.50
+603.1%
-53.8%$186.88M$90,000.000.002,021Gap Up
BCAB
BioAtla
2.446 of 5 stars
$3.66
+2.5%
$15.67
+328.1%
+21.7%$174.47M$250,000.00-1.3756Positive News
JSPR
Jasper Therapeutics
2.1389 of 5 stars
$1.57
-0.6%
$6.21
+295.7%
-45.9%$173.22MN/A-1.3925
PSTX
Poseida Therapeutics
1.8084 of 5 stars
$2.41
-5.5%
$16.00
+563.9%
-12.2%$209.14M$130.49M-3.95263
GRPH
Graphite Bio
1.5988 of 5 stars
$2.96
+0.3%
$3.33
+12.6%
+14.3%$171.98MN/A-1.6469
CCCC
C4 Therapeutics
1.583 of 5 stars
$3.49
+2.0%
$9.86
+182.4%
-52.2%$171.22M$31.10M-1.30121
GMDA
Gamida Cell
1.8426 of 5 stars
$2.29
-0.9%
$7.60
+231.9%
+0.9%$170.33MN/A-3.95166
GRTS
Gritstone bio
1.6095 of 5 stars
$2.38
+7.7%
$5.75
+141.6%
+7.3%$211.61M$19.94M-1.84193News Coverage
VXRT
Vaxart
1.6281 of 5 stars
$1.24
-2.4%
$4.75
+283.1%
-75.9%$168.14M$110,000.00-1.49110
ABOS
Acumen Pharmaceuticals
1.0361 of 5 stars
$5.20
+5.1%
$15.75
+202.9%
+23.6%$213.36M$1.44M-4.6814News Coverage

Related Companies and Tools

This page (NASDAQ:IPSC) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -